Therapeutic area
Musculoskeletal
Fibromyalgia: what a 2026 network meta-analysis of 151 drug trials shows
A 2026 network meta-analysis of 151 trials (32,592 adults) found low-certainty, typically small drug benefits and no pooled pain effect meeting a clinical importance threshold.
Osteoporosis: the 2025 USPSTF screening statement and how the ACP graded drug treatment in 2023
Screening older, higher-risk women was linked to fewer hip fractures (relative risk 0.83, 95% CI 0.73 to 0.93) and fewer major osteoporotic fractures (relative risk 0.94, 95% CI 0.88 to 0.99), corresponding to 5 to 6 fewer fractures per 1,000 screened, in the 2025 USPSTF evidence review.
Polymyalgia rheumatica: 2025 EULAR and 2026 British guidelines, plus new methotrexate, IL-6 receptor antagonist and ultrasound data
In a small 2026 placebo-controlled trial of recently diagnosed PMR (64 randomized, 58 analyzed), 80% on methotrexate versus 46% on placebo reached glucocorticoid-free remission at 52 weeks; a 2026 British guideline includes consideration of early methotrexate.